ImmuPharma (IMM) Stock Rating Reaffirmed by Northland Securities

ImmuPharma (LON:IMM)‘s stock had its “buy” rating restated by equities research analysts at Northland Securities in a research note issued to investors on Friday. They presently have a GBX 181 ($2.50) price target on the stock. Northland Securities’ target price would suggest a potential upside of 44.22% from the company’s previous close.

Separately, FinnCap reaffirmed a “buy” rating and issued a GBX 237 ($3.27) price target on shares of ImmuPharma in a research report on Thursday, December 21st.

How to Become a New Pot Stock Millionaire

ImmuPharma (LON:IMM) opened at GBX 125.50 ($1.73) on Friday. The stock has a market capitalization of $174.33 and a PE ratio of -3,137.50. ImmuPharma has a 52-week low of GBX 44 ($0.61) and a 52-week high of GBX 193.74 ($2.68).

COPYRIGHT VIOLATION WARNING: This report was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3298244/immupharma-imm-stock-rating-reaffirmed-by-northland-securities.html.

About ImmuPharma

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Comparing TearLab  and Its Rivals
Comparing TearLab and Its Rivals
Trinity Biotech  versus Its Competitors Financial Analysis
Trinity Biotech versus Its Competitors Financial Analysis
CasinoCoin  1-Day Volume Hits $26,581.00
CasinoCoin 1-Day Volume Hits $26,581.00
ENTCash  24-Hour Trading Volume Hits $9,964.00
ENTCash 24-Hour Trading Volume Hits $9,964.00
Caterpillar  Raised to A- at TheStreet
Caterpillar Raised to A- at TheStreet
Aspen Group  Given “Buy” Rating at Roth Capital
Aspen Group Given “Buy” Rating at Roth Capital


© 2006-2018 Ticker Report. Google+.